Anna Bagnato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5874551/publications.pdf

Version: 2024-02-01

61857 76769 5,786 112 43 74 citations h-index g-index papers 112 112 112 4855 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The endothelin axis: emerging role in cancer. Nature Reviews Cancer, 2003, 3, 110-116.	12.8	527
2	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	1.9	322
3	Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer, 2013, 13, 637-651.	12.8	282
4	Role of Endothelin-1 in Neovascularization of Ovarian Carcinoma. American Journal of Pathology, 2000, 157, 1537-1547.	1.9	184
5	Endothelin-1 Induces Vascular Endothelial Growth Factor by Increasing Hypoxia-inducible Factor-1α in Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2002, 277, 27850-27855.	1.6	182
6	The endothelin axis in cancer. International Journal of Biochemistry and Cell Biology, 2008, 40, 1443-1451.	1.2	172
7	Acquisition of Chemoresistance and EMT Phenotype Is Linked with Activation of the Endothelin A Receptor Pathway in Ovarian Carcinoma Cells. Clinical Cancer Research, 2011, 17, 2350-2360.	3.2	167
8	Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells. Cancer Research, 2005, 65, 11649-11657.	0.4	161
9	\hat{l}^2 -Arrestin links endothelin A receptor to \hat{l}^2 -catenin signaling to induce ovarian cancer cell invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2806-2811.	3.3	159
10	Endothelin-1 Protects Ovarian Carcinoma Cells against Paclitaxel-Induced Apoptosis: Requirement for Akt Activation. Molecular Pharmacology, 2002, 61, 524-532.	1.0	132
11	Emerging role of endothelin-1 in tumor angiogenesis. Trends in Endocrinology and Metabolism, 2003, 14, 44-50.	3.1	123
12	Endothelin B Receptor Blockade Inhibits Dynamics of Cell Interactions and Communications in Melanoma Cell Progression. Cancer Research, 2004, 64, 1436-1443.	0.4	115
13	Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology, 2011, 163, 220-233.	2.7	103
14	Endothelin receptors as novel targets in tumor therapy. Journal of Translational Medicine, 2004, 2, 16.	1.8	96
15	Endothelin-1-induced Prostaglandin E2-EP2, EP4 Signaling Regulates Vascular Endothelial Growth Factor Production and Ovarian Carcinoma Cell Invasion. Journal of Biological Chemistry, 2004, 279, 46700-46705.	1.6	91
16	Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Research, 2003, 63, 2447-53.	0.4	90
17	Endothelin A Receptor/β-Arrestin Signaling to the Wnt Pathway Renders Ovarian Cancer Cells Resistant to Chemotherapy. Cancer Research, 2014, 74, 7453-7464.	0.4	89
18	Endothelin-1 Stimulates Lymphatic Endothelial Cells and Lymphatic Vessels to Grow and Invade. Cancer Research, 2009, 69, 2669-2676.	0.4	87

#	Article	IF	CITATIONS
19	Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1α in Human Melanoma Cells. Cancer Research, 2007, 67, 1725-1734.	0.4	84
20	Emerging role of the endothelin axis in ovarian tumor progression. Endocrine-Related Cancer, 2005, 12, 761-772.	1.6	80
21	\hat{l}^2 -arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced \hat{l}^2 -catenin signaling. Oncogene, 2013, 32, 5066-5077.	2.6	79
22	The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapyThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin Canadian Journal of Physiology and Pharmacology, 2008, 86, 473-484.	0.7	78
23	Endothelins as Autocrine Regulators of Tumor Cell Growth. Trends in Endocrinology and Metabolism, 1998, 9, 378-383.	3.1	74
24	Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 833-842.	1.9	74
25	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 1483-1492.	1.9	73
26	Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Research, 2002, 62, 6381-4.	0.4	67
27	Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity. Cancer Research, 2007, 67, 6351-6359.	0.4	65
28	Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology, 1992, 130, 1097-1102.	1.4	65
29	Endothelin-1 Decreases Gap Junctional Intercellular Communication by Inducing Phosphorylation of Connexin 43 in Human Ovarian Carcinoma Cells. Journal of Biological Chemistry, 2003, 278, 41294-41301.	1.6	64
30	\hat{l}^2 -Arrestin 1 is required for endothelin-1-induced NF- \hat{l}^0 B activation in ovarian cancer cells. Life Sciences, 2014, 118, 179-184.	2.0	64
31	Epithelial-Mesenchymal Transition in Ovarian Cancer Progression: A Crucial Role for the Endothelin Axis. Cells Tissues Organs, 2007, 185, 85-94.	1.3	63
32	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. Journal of Molecular Medicine, 2013, 91, 83-94.	1.7	63
33	β-Arrestin-1 Drives Endothelin-1–Mediated Podocyte Activation and Sustains Renal Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 523-533.	3.0	63
34	Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells. Clinical Cancer Research, 2004, 10, 4670-4679.	3.2	62
35	ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Molecular Cancer Therapeutics, 2007, 6, 2003-2011.	1.9	61
36	Expression of endothelin 1 and endothelin A receptor in HPVâ€associated cervical carcinoma: new potential targets for anticancer therapy. FASEB Journal, 2000, 14, 2277-2283.	0.2	57

3

#	Article	IF	Citations
37	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. American Journal of Pathology, 2003, 163, 753-762.	1.9	55
38	Endothelin A receptor drives invadopodia function and cell motility through the \hat{l}^2 -arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene, 2016, 35, 3432-3442.	2.6	53
39	Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1α in Melanoma Cells. PLoS ONE, 2010, 5, e11241.	1.1	50
40	miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget, 2016, 7, 4009-4023.	0.8	49
41	Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. Journal of Molecular Medicine, 2013, 91, 395-405.	1.7	48
42	\hat{l}^2 -arrestin1 at the cross-road of endothelin-1 signaling in cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 121.	3.5	47
43	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. Nucleic Acids Research, 2014, 42, 2945-2957.	6.5	45
44	The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis, 2014, 35, 840-848.	1.3	44
45	The E5 Oncoprotein of Human Papillomavirus Type 16 Enhances Endothelin-1-Induced Keratinocyte Growth. Virology, 1998, 248, 1-5.	1.1	41
46	\hat{l}^2 -arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer. Nature Communications, 2019, 10, 3196.	5.8	40
47	Effect of adriamycin on electron transport in rat heart, liver, and tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 123-135.	0.9	39
48	Endothelin therapeutics in cancer: Where are we?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R469-R475.	0.9	38
49	New Routes in GPCR/ \hat{I}^2 -Arrestin-Driven Signaling in Cancer Progression and Metastasis. Frontiers in Pharmacology, 2019, 10, 114.	1.6	38
50	Tumor Cellular and Microenvironmental Cues Controlling Invadopodia Formation. Frontiers in Cell and Developmental Biology, 2020, 8, 584181.	1.8	35
51	Endothelin Receptor Blockade Inhibits Proliferation of Kaposi's Sarcoma Cells. American Journal of Pathology, 2001, 158, 841-847.	1.9	34
52	Blocking endothelin-1-receptor/ \hat{l}^2 -catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death and Differentiation, 2017, 24, 1811-1820.	5.0	34
53	Nuclear \hat{l}^2 -arrestin1 is a critical cofactor of hypoxia-inducible factor- $1\hat{l}^2$ signaling in endothelin-1-induced ovarian tumor progression. Oncotarget, 2016, 7, 17790-17804.	0.8	33
54	Gonadotropin-Induced Expression of Receptors for Growth Hormone Releasing Factor in Cultured Granulosa Cells*. Endocrinology, 1991, 128, 2889-2894.	1.4	32

#	Article	IF	Citations
55	Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clinical Science, 2002, 103, 306S-309S.	1.8	31
56	Identification of the ETA Receptor Subtype That Mediates Endothelin-Induced Autocrine Proliferation of Normal Human Keratinocytes. Biochemical and Biophysical Research Communications, 1995, 209, 80-86.	1.0	29
57	\hat{l}^2 -arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinaseThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 796-801.	0.7	28
58	The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R395-R404.	0.9	25
59	Understanding and Overcoming Chemoresistance in Ovarian Cancer: Emerging Role of the Endothelin Axis. Current Oncology, 2012, 19, 36-38.	0.9	25
60	Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sciences, 2016, 159, 43-48.	2.0	25
61	Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clinical Science, 2002, 103, 302S-305S.	1.8	24
62	Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. Matrix Biology, 2019, 81, 17-33.	1.5	23
63	YAP and endothelin-1 signaling: an emerging alliance in cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 27.	3.5	23
64	ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth <i>in vitro</i> Clinical Science, 2002, 103, 318S-321S.	1.8	21
65	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. Molecular Cancer Therapeutics, 2014, 13, 916-925.	1.9	21
66	Endothelinâ€1 receptor blockade as new possible therapeutic approach in multiple myeloma. British Journal of Haematology, 2017, 178, 781-793.	1,2	21
67	hMENA is a key regulator in endothelin- $1/\hat{l}^2$ -arrestin $1\hat{a}$ induced invadopodial function and metastatic process. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3132-3137.	3.3	21
68	Endothelin-1 Stimulates Cyclooxygenase-2 Expression in Ovarian Cancer Cells Through Multiple Signaling Pathways: Evidence for Involvement of Transactivation of the Epidermal Growth Factor Receptor. Journal of Cardiovascular Pharmacology, 2004, 44, S140-S143.	0.8	20
69	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Gynecologic Oncology, 2013, 130, 31-37,	0.6	20
70	Modulation of adriamycin uptake by lonidamine in ehrlich ascites tumor cells. Experimental and Molecular Pathology, 1988, 49, 421-431.	0.9	19
71	Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 782-787.	0.7	19
72	Endothelin-1 regulates hypoxia-inducible factor-1α and -2α stability through prolyl hydroxylase domain 2 inhibition in human lymphatic endothelial cells. Life Sciences, 2014, 118, 185-190.	2.0	19

#	Article	IF	Citations
73	Targeting Endothelin-1 Receptor $\hat{\mathbb{I}}^2$ -Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach. Frontiers in Endocrinology, 2019, 10, 609.	1.5	19
74	Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Experimental Biology and Medicine, 2006, 231, 1128-31.	1.1	18
75	Targeting Endothelin Axis in Cancer. , 2004, 119, 293-314.		17
76	New insights into the regulation of the actin cytoskeleton dynamics by GPCR/ \hat{l}^2 -arrestin in cancer invasion and metastasis. International Review of Cell and Molecular Biology, 2019, 346, 129-155.	1.6	16
77	Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sciences, 2012, 91, 638-643.	2.0	15
78	Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Reports, 2021, 34, 108800.	2.9	15
79	Endothelin-1/endothelin A receptor axis activates RhoA GTPase in epithelial ovarian cancer. Life Sciences, 2016, 159, 49-54.	2.0	13
80	Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer. Communications Biology, 2020, 3, 677.	2.0	13
81	Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression. Journal of Cardiovascular Pharmacology, 2004, 44, S136-S139.	0.8	12
82	Endothelin-1 receptor drives invadopodia: Exploiting how \hat{l}^2 -arrestin-1 guides the way. Small GTPases, 2018, 9, 394-398.	0.7	12
83	Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Letters, 2020, 492, 84-95.	3.2	12
84	The autonomous growth of human papillomavirus type 16-immortalized keratinocytes is related to the endothelin-1 autocrine loop. Journal of Virology, 1997, 71, 6898-6904.	1.5	12
85	Convergent pathways link the endothelin A receptor to the \hat{l}^2 -catenin: The \hat{l}^2 -arrestin connection. Cell Cycle, 2009, 8, 1461-1465.	1.3	11
86	The endothelin A receptor and epidermal growth factor receptor signaling converge on \hat{l}^2 -catenin to promote ovarian cancer metastasis. Life Sciences, 2012, 91, 550-556.	2.0	11
87	Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Experimental Biology and Medicine, 2006, 231, 1123-7.	1.1	10
88	Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma. Clinical Science, 2002, 103, 310S-313S.	1.8	9
89	Targeting endothelin-1 receptor/ \hat{l}^2 -arrestin1 network for the treatment of ovarian cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 925-932.	1.5	9
90	In reply to SchÃÆr <i>etÂal</i> : new evidence on the role of endothelinâ€1 axis as a potential therapeutic target in multiple myeloma. British Journal of Haematology, 2019, 184, 1052-1055.	1.2	9

#	Article	IF	Citations
91	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 600025.	1.3	9
92	Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancerThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research Canadian Journal of Physiology and Pharmacology, 2010, 88, 676-681.	0.7	8
93	Therapeutic Targeting of the Endothelin-A Receptor in Human Ovarian Carcinoma: Efficacy of Cytotoxic Agents is Markedly Enhanced by Co-administration with Atrasentan. Journal of Cardiovascular Pharmacology, 2004, 44, \$132-\$135.	0.8	7
94	The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future. Current Pharmaceutical Design, 2012, 18, 2720-2733.	0.9	7
95	ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Experimental Biology and Medicine, 2006, 231, 1132-5.	1.1	7
96	Targeting Endothelin Receptor Type A in Human Cervical Carcinoma Cells. Journal of Cardiovascular Pharmacology, 2004, 44, S72-S75.	0.8	5
97	Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. Cell Cycle, 2009, 8, 1462-3.	1.3	5
98	Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 157.	3.5	5
99	Ovarian Cancer-Driven Mesothelial-to-Mesenchymal Transition is Triggered by the Endothelin- $1/\hat{l}^2$ -arr1 Axis. Frontiers in Cell and Developmental Biology, 2021, 9, 764375.	1.8	4
100	Effect of hyperthermia on electron transport in ehrlich ascites tumor mitochondria. Experimental and Molecular Pathology, 1987, 46, 279-293.	0.9	3
101	Disrupting the endothelin and Wnt relationship to overcome chemoresistance. Molecular and Cellular Oncology, 2015, 2, e995025.	0.3	3
102	Methods to Investigate \hat{l}^2 -Arrestin- $1/\hat{l}^2$ -Catenin Signaling in Ovarian Cancer Cells. Methods in Molecular Biology, 2019, 1957, 393-406.	0.4	2
103	Lost in translation: bridging the gap between cancer research and effective therapies. Cell Death and Differentiation, 2011, 18, 1082-1084.	5.0	1
104	Lonidamine-Induced Membrane Permeability and the Effect of Adriamycin on the Energy Metabolism of Ehrlich Ascites Tumor Cells. Annals of the New York Academy of Sciences, 1988, 551, 270-272.	1.8	0
105	Therapies for cancer targeting endothelin receptors. Drugs of the Future, 2003, 28, 983.	0.0	0
106	Abstract 698: \hat{l}^2 -arrestin-1 as nuclear signalling element essential for endothelin A receptor-induced epithelial to mesenchymal transition and chemoresistance., 2011,,.		0
107	Abstract 707: Acquisition of chemoresistance and epithelial to mesenchymal phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. , $2011,\ldots$		0
108	Abstract 3473: Endothelin axis autocrine loop is positively regulated by the interplay between ET-1 and hypoxia-inducible factor- \hat{l} in melanoma cells., 2011,,.		0

#	Article	IF	CITATIONS
109	Abstract 493: Endothelin-1 induces activation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. , 2012, , .		O
110	Abstract 3086: \hat{l}_{\pm} -arrestin-1 acts as a nuclear transcriptional regulator of endothelin A receptor signalling to promote ovarian cancer progression., 2012,,.		0
111	Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. , 2014, , .		O
112	Abstract 3144: PDZ-RhoGEF/ \hat{l}^2 -arrestin-1 interaction mediates endothelin A receptor-induced RhoA activation and cell motility in ovarian tumor cells. , 2014, , .		0